Provided by Tiger Fintech (Singapore) Pte. Ltd.

INNOVENT BIO

49.600
+2.3504.97%
Volume:3.30M
Turnover:164.02M
Market Cap:81.74B
PE:-803.03
High:50.250
Open:48.800
Low:48.050
Close:47.250
Loading ...

Nomura Adjusts Innovent Biologics' Price Target to HK$54.60 From HK$58.09, Keeps at Buy

MT Newswires Live
·
18 Feb

Innovent Receives Second Fast Track Designation From the U.S. FDA for Ibi363 (Pd-1/Il-2Α-Bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer

THOMSON REUTERS
·
17 Feb

Innovent Biologics' Near-Term Stock Performance May Depend on New Drug Products -- Market Talk

Dow Jones
·
10 Feb

Innovent Biologics Logs 25% Boost in Q4 2024 Product Revenue

MT Newswires Live
·
06 Feb

Innovent Biologics - Expected Result Due to Continued Fast Growth of Major Products, Others

THOMSON REUTERS
·
06 Feb

Innovent Biologics - for FY Total Product Revenue Amounted to More Than RMB8.2 Bln

THOMSON REUTERS
·
06 Feb

Stock Track | Innovent Biologics Soars 5% as New Lung Cancer Drug Limertinib Gets China Approval

Stock Track
·
17 Jan

Innovent Biologics Gets China Approval for Non-Small-Cell Lung Cancer Drug; Shares Rise 3%

MT Newswires Live
·
17 Jan

BUZZ-Innovent Biologics rises as regulator approves co's product for cancer treatment

Reuters
·
17 Jan

BRIEF-Innovent Biologics Says Third-Generation EGFR TKI Limertinib Received Approval By NMPA China

Reuters
·
17 Jan

Innovent and Ask Pharm Jointly Announce Nmpa Approval of Limertinib, a Third-Generation Egfr Tki for the Treatment of Lung Cancer

THOMSON REUTERS
·
17 Jan

Innovent Biologics - Third-Generation Egfr Tki Limertinib Received- Approval by Nmpa China

THOMSON REUTERS
·
17 Jan

BUZZ-Innovent climbs as China regulator approves new drug application

Reuters
·
03 Jan

Innovent Bio's NSCLC Drug Gets China Approval

MT Newswires Live
·
03 Jan

BRIEF-Innovent Biologics Says Nmpa Approves Second New Drug Application Of Ros1 Inhibitor Dovbleron

Reuters
·
03 Jan

Innovent Biologics - Nmpa Approves Second New Drug Application of Ros1 Inhibitor Dovbleron

THOMSON REUTERS
·
03 Jan

Innovent Bio Grants Roche Exclusive Global Rights to ADC Targeting DLL3

MT Newswires Live
·
02 Jan

BRIEF-Innovent Biologics Announces Entering Into Exclusive Global License Agreement

Reuters
·
02 Jan

Innovent Biologics - Entering Into Exclusive Global License Agreement With Roche for Novel Dll3 ADC

THOMSON REUTERS
·
02 Jan

Revenues Working Against Innovent Biologics, Inc.'s (HKG:1801) Share Price

Simply Wall St.
·
28 Dec 2024